LSN Summer Reading Series Chapter 7: “Establishing a Web Presence”

~ Next Phase Admin ~ Leave a comment

By Shaoyu Chang, MD, MPH,  Senior Research Analyst, LSN

Shaoyu 10*10If investors find interest in your slide deck and executive summary, what is the next thing they typically do? They look you up on the internet. A fundraising entrepreneur would not want to miss out on this opportunity to connect with interested investors. As a key component of your branding and messaging strategy, a good website provides a fully integrated and interactive package of information about your story, technology, team, and most recent updates. In this week’s edition of summer reading series, we will explore the issues a life science executive must consider when creating a strong web presence.

Chapter 7 of The Life Science Executive’s Fundraising Manifesto, “Establishing a Web Presence,” discusses what makes a simple and effective website, whether to do it yourself or hire a web designer, how to employ search engine optimization to drive traffic to your site, and the importance of constantly managing and updating your content.

Click here to download/print the PDF.

Over the past few weeks, we have laid the groundwork for a marketing campaign. Join us next week as we go outbound in Chapter 8, “Leveraging Cloud Infrastructure to Manage an Outbound Campaign,” where we identify useful tools for managing your outbound activities.

Enjoyed the preview? Buy now from Amazon.com or Barnes & Noble

Bookcover-Front

Hot Life Science Investor Mandate 1: European VC Raises New Life Science Fund

~ Next Phase Admin ~ Leave a comment

A venture capital firm that was founded in 2008 based in Europe with an additional office in New York City manages €176 million in total assets across two funds. The firm recently held a first close of its second fund at €103 million. The firm typically makes equity investment into early-stage life science companies. The typical investment size ranges from €0.5million-€7million ($0.7million-$10million). The second fund looks to make 10 to 15 investments. The firm generally invests in companies based in the US and Europe.

The venture capital firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics, Diagnostics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications, and it is most interested in companies in pre-clinical and clinical stages. In the past, the firm was active in therapeutic and diagnostic companies developing drug delivery and gene therapy technologies. The firm was also active in device companies developing single use devices and non-active implantable devices.

The firm primarily invests in private companies with experienced management teams, but it will also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Life Science Investor Mandate 2: Large Angel Network Seeking Medtech, Diagnostic and Healthcare IT Opportunities

~ Next Phase Admin ~ Leave a comment

A 100-member angel network based in the USA has invested over $60 million in almost 200 deals.  The group considers early stage companies in a wide range of industry sectors including life sciences. The group can either lead or co-invest in a financing round from $25K to up to $500K per deal. Investments are made in convertible preferred equity or convertible notes depending on the deal. The group is seeking new opportunities across the US.

Within life sciences, the angel network is most interested in early stage medical device, diagnostic, and healthcare IT innovations. The group considers medical devices at all risk levels and is agnostic to disease indications. The group would also consider therapeutics, but with less interest as the development timeline and risks of early stage therapeutics are often not suitable for the group.

The angel network is looking for competent entrepreneurs with sector expertise. The group seeks active participation after investment and can help build the management team when needed. The group typically avoids crowdfunded investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Life Science Investor Mandate 3: VC Seeks Medical Devices and Healthcare Services for Chinese Market

~ Next Phase Admin ~ Leave a comment

A China-based healthcare-specific RMB fund has raised three funds to date and is now investing from its recently closed third fund. The firm is actively seeking to invest in early-growth and revenue-stage China-based companies, and also considers offshore companies that have significant operations in China or products that are strongly applicable to the Chinese market.

The firm is currently seeking companies in the healthcare service sector, which includes healthcare record management systems, healthcare IT, and mobile health. The firm is also interested in innovative medical devices that have large market potential. The firm is agnostic to therapeutic indications, but is not interested in large hospital equipment. The firm looks for companies that have “disruptive” technologies and/or products or business models that are game-changing. The firm prefers early-growth and revenue-stage companies, while it also invest in select early ventures that seek to establish critical infrastructures and platforms in the evolving Chinese healthcare industry.

The firm invests in entrepreneurs who have unique insights, exceptional domain knowledge and deep operational experience. In particular, the firm looks for management teams with successful track records in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Life Science Investor Mandate 4: Corporate VC Fund Seeks Novel Healthcare Technologies Including Cell and Gene Therapies

~ Next Phase Admin ~ Leave a comment

The corporate VC arm of a large pharmaceutical company manages an evergreen fund with $400 million in assets under management. The firm looks to make investments generally in seed and Series A rounds with up to $10 million initially and up to $25 over the lifetime of the investment. The firm is open to reviewing opportunities from all around the globe.

The firm is currently interested in companies operating in sectors of therapeutics, diagnostics, medical devices and healthcare IT. The firm is fairly open to all types of technologies within these sectors pending that it be truly novel. The firm is not interested in pure reformulations or repurposing plays, and a higher level of interested in the cell and gene therapy spaces. For therapeutics the firm generally looks for companies in either pre-clinical or phase I of clinical development and for devices and diagnostics the firm will generally considers those that are in the clinical or already on the market. Only in cases of drug delivery devices would the firm look early than the clinical stage for devices. The firm is also open to technologies in all indication areas but generally only consider technologies targeting crowded spaces such as diabetes and Alzheimer’s if they are truly disruptive.

The firm is looking for privately held companies with experienced management teams and always look to take a board seat following investment. From time to time members of the firm have acted as management within portfolio companies as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Back to Boston and Bigger than Ever: RESI Conference on September 16th

~ Next Phase Admin ~ Leave a comment

By Lucy Parkinson, Senior Research Manager, LSN 

lucy 10*10The first Redefining Early Stage Investments (RESI) Conference took place on September 16, 2013, and two years later, following highly successful events in San Francisco and Houston, we return to Boston for the sixth RESI Conference. With new and returning sponsors including Johnson & Johnson Innovation JLABS, Charles River Laboratories, McDermott Will & Emory, and Wuxi AppTec, we expect this event to be the largest RESI so far, with more content and more meetings than ever.

The RESI Conference Series was founded with the goal of creating meetings based on a common fit. Our experience shows that starting with fit, and then finding a targeted alignment between entrepreneurs and investors, leads to compelling conversations; RESI’s mission is to provide a venue for those conversations to begin and develop. By connecting early stage life science fundraising executives with the right investors, RESI is where qualified fundraising relationships arise.

LSN’s CEO, Dennis Ford, says, “We want to inundate the attendees of RESI Boston with more amazing opportunities than they can handle, including one-on-one investor meetings, firsthand information from RESI’s early stage investor panels, and tactical guidance from fundraising workshops—because if we’re doing that, we’re doing our job. We want to provide a huge amount of relevant content to everyone, on one day. RESI’s goal is to give the fundraising CEOs and scientist entrepreneurs in this early stage investment world as much value as possible.”

RESI Boston offers entrepreneurs the opportunity to schedule up to 16 meetings with investors through the RESI Partnering Platform; and in addition to these face-to-face meetings, 20+ panels and workshops focused on various aspects of fundraising and investment will provide platforms for investors and industry veterans to share valuable insights with fundraising entrepreneurs.

If you’d like to be part of the largest RESI ever, you can register before 7/31/2015 at the Early Bird Rate here.

RESI-Boston-wp

RESI@TMCX Medtech Family Offices Panel

~ Next Phase Admin ~ Leave a comment

By Shaoyu Chang, MD, MPH,  Senior Research Analyst, LSN

Shaoyu 10*10On the heels of last weeks Biotech Family Offices Panel Video from RESI @TMCX we bring you our Medtech Family offices video. Hear firsthand accounts from these family office investors in the medical device space regarding the types and stages of companies they are looking for and how to go about getting in touch with them.

Click on the video below to hear the views of these family office speakers for yourself.